Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2018 December;153(6) > Giornale Italiano di Dermatologia e Venereologia 2018 December;153(6):764-75

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE  PDT FOR NON-MELANOMA SKIN CANCER Freefree

Giornale Italiano di Dermatologia e Venereologia 2018 December;153(6):764-75

DOI: 10.23736/S0392-0488.18.06071-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Evaluation of the costs of topical treatments for actinic keratosis based on lesion response and the affected area

Piergiacomo CALZAVARA-PINTON 1 , Cristina ZANE 1, Mariachiara ARISI 1, Pol-Antoine HAMON 2, Neda T. TANOVA 3

1 Department of Dermatology, University of Brescia, Brescia, Italy; 2 Galderma, Paris, France; 3 Amaris, London, UK



BACKGROUND: The cost of topical treatments for actinic keratosis (AK) has never been evaluated with respect to the actual cancerization field treated and the corresponding lesion response rate. Traditionally, evaluation in AK has been done in the context of patient response rate alone. The current study aimed to develop an economic model assessing the cost of topical treatments for the management of AK in Italy.
METHODS: Data from Italian patients (N.=100) with five or more mild/moderate lesions on the face and/or scalp was used. The efficacy of the topical treatments which are available for the treatment of AK in Italy was considered. The outcome of interest was lesion response rates at three months and was based on published literature. The cost of each treatment was estimated according to the approval status of the drug and the cancerization area that required treatment. The analysis was replicated for four other European countries.
RESULTS: The average costs of treatment with c-PDT, DL PDT, DHA, InMeb and IMQ were € 364.2, € 255.5, € 848.7, € 1039.1, and € 628.3, respectively. Taking into account the number of lesions cleared per patient, the cancerization area treated, and the number of visits required with each treatment, the total costs per lesion treated per patient were estimated at € 37.9, € 29, € 264.7, € 103.5, and € 115.4, respectively. The analysis produced consistent results when it was replicated for other countries.
CONCLUSIONS: Daylight therapy with methyl aminolevulinate (DL PDT) is an effective treatment option for AK management with a favourable value for money profile.


KEY WORDS: Actinic keratosis - Photochemotherapy - Health care costs

top of page